Trial Watch

References

• Song WY, Wang GL, Chen LL, Kim HS, Pi LY, Holsten T, Gardner J, Wang B, Zhai WX, Zhu LH, et al. A receptor kinase-like protein encoded by the rice disease resistance gene, Xa21. Science 1995; 270:1804 - 6; http://dx.doi.org/10.1126/science.270.5243.1804; PMID: 8525370
   PubMed Web of Science ®Google Scholar
• Gómez-Gómez L, Boller T. FLS2: an LRR receptor-like kinase involved in the perception of the bacterial elicitor flagellin in Arabidopsis. Mol Cell 2000; 5:1003 - 11; http://dx.doi.org/10.1016/S1097-2765(00)80265-8; PMID: 10911994
   PubMed Web of Science ®Google Scholar
• Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 2005; 102:9577 - 82; http://dx.doi.org/10.1073/pnas.0502272102; PMID: 15976025
   PubMed Web of Science ®Google Scholar
• Anderson KV, Bokla L, Nüsslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 1985; 42:791 - 8; http://dx.doi.org/10.1016/0092-8674(85)90275-2; PMID: 3931919
   PubMed Web of Science ®Google Scholar
• Anderson KV, Jürgens G, Nüsslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 1985; 42:779 - 89; http://dx.doi.org/10.1016/0092-8674(85)90274-0; PMID: 3931918
   PubMed Web of Science ®Google Scholar
• Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86:973 - 83; http://dx.doi.org/10.1016/S0092-8674(00)80172-5; PMID: 8808632
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637 - 50; http://dx.doi.org/10.1016/j.immuni.2011.05.006; PMID: 21616434
   PubMed Web of Science ®Google Scholar
• Hennessy EJ, Parker AE, O’Neill LA. Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov 2010; 9:293 - 307; http://dx.doi.org/10.1038/nrd3203; PMID: 20380038
   PubMed Web of Science ®Google Scholar
• Lauw FN, Caffrey DR, Golenbock DT. Of mice and man: TLR11 (finally) finds profilin. Trends Immunol 2005; 26:509 - 11; http://dx.doi.org/10.1016/j.it.2005.08.006; PMID: 16111920
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. OncoImmunology 2012; 1:699 - 716; http://dx.doi.org/10.4161/onci.20696; PMID: 22934262
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. OncoImmunology 2012; 1:894 - 907; http://dx.doi.org/10.4161/onci.20931; PMID: 23162757
   PubMed Web of Science ®Google Scholar
• Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 2000; 165:3541 - 4; http://dx.doi.org/10.4049/jimmunol.165.7.3541; PMID: 11034352
   PubMed Web of Science ®Google Scholar
• Schröder NW, Opitz B, Lamping N, Michelsen KS, Zähringer U, Göbel UB, Schumann RR. Involvement of lipopolysaccharide binding protein, CD14, and Toll-like receptors in the initiation of innate immune responses by Treponema glycolipids. J Immunol 2000; 165:2683 - 93; http://dx.doi.org/10.4049/jimmunol.165.5.2683; PMID: 10946299
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316:1628 - 32; http://dx.doi.org/10.1126/science.1138963; PMID: 17569868
   PubMed Web of Science ®Google Scholar
• Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, Hartung T, Zähringer U, et al. CD36 is a sensor of diacylglycerides. Nature 2005; 433:523 - 7; http://dx.doi.org/10.1038/nature03253; PMID: 15690042
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099 - 103; http://dx.doi.org/10.1038/35074106; PMID: 11323673
   PubMed Web of Science ®Google Scholar
• Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, Cookson BT, Aderem A. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003; 4:1247 - 53; http://dx.doi.org/10.1038/ni1011; PMID: 14625549
   PubMed Web of Science ®Google Scholar
• Lu J, Sun PD. The structure of the TLR5-flagellin complex: a new mode of pathogen detection, conserved receptor dimerization for signaling. Sci Signal 2012; 5:pe11; http://dx.doi.org/10.1126/scisignal.2002963
   PubMed Web of Science ®Google Scholar
• Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA. Structural basis of TLR5-flagellin recognition and signaling. Science 2012; 335:859 - 64; http://dx.doi.org/10.1126/science.1215584; PMID: 22344444
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740 - 5; http://dx.doi.org/10.1038/35047123; PMID: 11130078
   PubMed Web of Science ®Google Scholar
• Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529 - 31; http://dx.doi.org/10.1126/science.1093616; PMID: 14976261
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526 - 9; http://dx.doi.org/10.1126/science.1093620; PMID: 14976262
   PubMed Web of Science ®Google Scholar
• Hotz C, Bourquin C. Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything. OncoImmunology 2012; 1:227 - 8; http://dx.doi.org/10.4161/onci.1.2.18169; PMID: 22720251
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732 - 8; http://dx.doi.org/10.1038/35099560; PMID: 11607032
   PubMed Web of Science ®Google Scholar
• Choe J, Kelker MS, Wilson IA. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 2005; 309:581 - 5; http://dx.doi.org/10.1126/science.1115253; PMID: 15961631
   PubMed Web of Science ®Google Scholar
• Liu L, Botos I, Wang Y, Leonard JN, Shiloach J, Segal DM, Davies DR. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008; 320:379 - 81; http://dx.doi.org/10.1126/science.1155406; PMID: 18420935
   PubMed Web of Science ®Google Scholar
• Shi Z, Cai Z, Yu J, Zhang T, Zhao S, Smeds E, Zhang Q, Wang F, Zhao C, Fu S, et al. Toll-like receptor 11 (TLR11) prevents Salmonella penetration into the murine Peyer patches. J Biol Chem 2012; 287:43417 - 23; http://dx.doi.org/10.1074/jbc.M112.411009; PMID: 23135279
   PubMed Web of Science ®Google Scholar
• Oldenburg M, Krüger A, Ferstl R, Kaufmann A, Nees G, Sigmund A, Bathke B, Lauterbach H, Suter M, Dreher S, et al. TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science 2012; 337:1111 - 5; http://dx.doi.org/10.1126/science.1220363; PMID: 22821982
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301 - 5; http://dx.doi.org/10.1126/science.1071059; PMID: 11951032
   PubMed Web of Science ®Google Scholar
• Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10:826 - 37; http://dx.doi.org/10.1038/nri2873; PMID: 21088683
   PubMed Web of Science ®Google Scholar
• Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59:583 - 94; http://dx.doi.org/10.1016/j.jhep.2013.03.033; PMID: 23567086
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780 - 8; http://dx.doi.org/10.1038/nrm3479; PMID: 23175281
   PubMed Web of Science ®Google Scholar
• Spel L, Boelens JJ, Nierkens S, Boes M. Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. OncoImmunology 2013; 2:e26403; http://dx.doi.org/10.4161/onci.26403; PMID: 24482744
   PubMedGoogle Scholar
• Yi Y, Zhou Z, Shu S, Fang Y, Twitty C, Hilton TL, Aung S, Urba WJ, Fox BA, Hu HM, et al. Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. OncoImmunology 2012; 1:976 - 8; http://dx.doi.org/10.4161/onci.20059; PMID: 23162777
   PubMed Web of Science ®Google Scholar
• Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002; 277:15028 - 34; http://dx.doi.org/10.1074/jbc.M200497200; PMID: 11836257
   PubMed Web of Science ®Google Scholar
• Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000; 164:13 - 7; http://dx.doi.org/10.4049/jimmunol.164.1.13; PMID: 10604986
   PubMed Web of Science ®Google Scholar
• Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 2005; 174:5016 - 23; http://dx.doi.org/10.4049/jimmunol.174.8.5016; PMID: 15814732
   PubMed Web of Science ®Google Scholar
• Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002; 168:5989 - 92; http://dx.doi.org/10.4049/jimmunol.168.12.5989; PMID: 12055204
   PubMed Web of Science ®Google Scholar
• Loser K, Vogl T, Voskort M, Lueken A, Kupas V, Nacken W, Klenner L, Kuhn A, Foell D, Sorokin L, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010; 16:713 - 7; http://dx.doi.org/10.1038/nm.2150; PMID: 20473308
   PubMed Web of Science ®Google Scholar
• Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13:1042 - 9; http://dx.doi.org/10.1038/nm1638; PMID: 17767165
   PubMed Web of Science ®Google Scholar
• Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009; 9:535 - 42; http://dx.doi.org/10.1038/nri2587; PMID: 19556980
   PubMed Web of Science ®Google Scholar
• Marques PE, Amaral SS, Pires DA, Nogueira LL, Soriani FM, Lima BH, Lopes GA, Russo RC, Avila TV, Melgaço JG, et al. Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure. Hepatology 2012; 56:1971 - 82; http://dx.doi.org/10.1002/hep.25801; PMID: 22532075
   PubMed Web of Science ®Google Scholar
• Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104 - 7; http://dx.doi.org/10.1038/nature08780; PMID: 20203610
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413:78 - 83; http://dx.doi.org/10.1038/35092578; PMID: 11544529
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr.. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2:253 - 8; http://dx.doi.org/10.1016/S1097-2765(00)80136-7; PMID: 9734363
   PubMed Web of Science ®Google Scholar
• Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, Mudd S, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003; 424:743 - 8; http://dx.doi.org/10.1038/nature01889; PMID: 12872135
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301:640 - 3; http://dx.doi.org/10.1126/science.1087262; PMID: 12855817
   PubMed Web of Science ®Google Scholar
• Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434:772 - 7; http://dx.doi.org/10.1038/nature03464; PMID: 15800576
   PubMed Web of Science ®Google Scholar
• Yanai H, Negishi H, Taniguchi T. The IRF family of transcription factors: Inception, impact and implications in oncogenesis. OncoImmunology 2012; 1:1376 - 86; http://dx.doi.org/10.4161/onci.22475; PMID: 23243601
   PubMed Web of Science ®Google Scholar
• Ksienzyk A, Neumann B, Kröger A. IRF-1 is critical for IFNγ mediated immune surveillance. OncoImmunology 2012; 1:533 - 4; http://dx.doi.org/10.4161/onci.19405; PMID: 22754776
   PubMed Web of Science ®Google Scholar
• Siednienko J, Gajanayake T, Fitzgerald KA, Moynagh P, Miggin SM. Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN-β and RANTES production. J Immunol 2011; 186:2514 - 22; http://dx.doi.org/10.4049/jimmunol.1003093; PMID: 21248248
   PubMed Web of Science ®Google Scholar
• Siednienko J, Halle A, Nagpal K, Golenbock DT, Miggin SM. TLR3-mediated IFN-β gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like. Eur J Immunol 2010; 40:3150 - 60; http://dx.doi.org/10.1002/eji.201040547; PMID: 20957750
   PubMed Web of Science ®Google Scholar
• Zambirinis CP, Miller G. Signaling via MYD88 in the pancreatic tumor microenvironment: A double-edged sword. OncoImmunology 2013; 2:e22567; http://dx.doi.org/10.4161/onci.22567; PMID: 23483804
   PubMedGoogle Scholar
• Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol 2012; 12:168 - 79; PMID: 22301850
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7:353 - 64; http://dx.doi.org/10.1038/nri2079; PMID: 17457343
   PubMed Web of Science ®Google Scholar
• Seya T, Shime H, Takaki H, Azuma M, Oshiumi H, Matsumoto M. TLR3/TICAM-1 signaling in tumor cell RIP3-dependent necroptosis. OncoImmunology 2012; 1:917 - 23; http://dx.doi.org/10.4161/onci.21244; PMID: 23162759
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9:57 - 63; http://dx.doi.org/10.1038/nrc2541; PMID: 19052556
   PubMed Web of Science ®Google Scholar
• Jinushi M. The role of innate immune signals in antitumor immunity. OncoImmunology 2012; 1:189 - 94; http://dx.doi.org/10.4161/onci.1.2.18495; PMID: 22720240
   PubMed Web of Science ®Google Scholar
• Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M, Hirata I, Nakano H. Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 2007; 98:1790 - 4; http://dx.doi.org/10.1111/j.1349-7006.2007.00590.x; PMID: 17711514
   PubMed Web of Science ®Google Scholar
• Mollaki V, Georgiadis T, Tassidou A, Ioannou M, Daniil Z, Koutsokera A, Papathanassiou AA, Zintzaras E, Vassilopoulos G. Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin’s lymphoma: a candidate-gene association study. J Hum Genet 2009; 54:655 - 9; http://dx.doi.org/10.1038/jhg.2009.90; PMID: 19745833
   PubMed Web of Science ®Google Scholar
• Gast A, Bermejo JL, Claus R, Brandt A, Weires M, Weber A, Plass C, Sucker A, Hemminki K, Schadendorf D, et al. Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS ONE 2011; 6:e24370; http://dx.doi.org/10.1371/journal.pone.0024370; PMID: 21931695
   PubMedGoogle Scholar
• Guirado M, Gil H, Saenz-Lopez P, Reinboth J, Garrido F, Cozar JM, Ruiz-Cabello F, Carretero R. Association between C13ORF31, NOD2, RIPK2 and TLR10 polymorphisms and urothelial bladder cancer. Hum Immunol 2012; 73:668 - 72; http://dx.doi.org/10.1016/j.humimm.2012.03.006; PMID: 22504414
   PubMed Web of Science ®Google Scholar
• Junjie X, Songyao J, Minmin S, Yanyan S, Baiyong S, Xiaxing D, Jiabin J, Xi Z, Hao C. The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer 2012; 12:57; http://dx.doi.org/10.1186/1471-2407-12-57; PMID: 22309608
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Almeida AJ, Osório NS, Saraiva M, Teixeira-Coelho M, Pedreiro S, Torrado E, Domingues N, Gomes-Alves AG, et al. The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes Immun 2012; 13:197 - 201; http://dx.doi.org/10.1038/gene.2011.59; PMID: 21866115
   PubMed Web of Science ®Google Scholar
• Kim MK, Park SW, Kim SK, Park HJ, Eun YG, Kwon KH, Kim J. Association of Toll-like receptor 2 polymorphisms with papillary thyroid cancer and clinicopathologic features in a Korean population. J Korean Med Sci 2012; 27:1333 - 8; http://dx.doi.org/10.3346/jkms.2012.27.11.1333; PMID: 23166414
   PubMed Web of Science ®Google Scholar
• Yang ZH, Dai Q, Gu YJ, Guo QX, Gong L. Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma. Cancer Sci 2012; 103:653 - 8; http://dx.doi.org/10.1111/j.1349-7006.2012.02210.x; PMID: 22320262
   PubMed Web of Science ®Google Scholar
• Resler AJ, Malone KE, Johnson LG, Malkki M, Petersdorf EW, McKnight B, Madeleine MM. Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. BMC Cancer 2013; 13:219; http://dx.doi.org/10.1186/1471-2407-13-219; PMID: 23634849
   PubMed Web of Science ®Google Scholar
• Roszak A, Lianeri M, Sowińska A, Jagodziński PP. Involvement of Toll-like Receptor 9 polymorphism in cervical cancer development. Mol Biol Rep 2012; 39:8425 - 30; http://dx.doi.org/10.1007/s11033-012-1695-8; PMID: 22714906
   PubMed Web of Science ®Google Scholar
• Agúndez JA, García-Martín E, Devesa MJ, Carballo M, Martínez C, Lee-Brunner A, Fernández C, Díaz-Rubio M, Ladero JM. Polymorphism of the TLR4 gene reduces the risk of hepatitis C virus-induced hepatocellular carcinoma. Oncology 2012; 82:35 - 40; http://dx.doi.org/10.1159/000335606; PMID: 22286521
   PubMed Web of Science ®Google Scholar
• Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM, Mitchell HM. The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis. PLoS ONE 2013; 8:e60327; http://dx.doi.org/10.1371/journal.pone.0060327; PMID: 23565226
   PubMedGoogle Scholar
• Kim HJ, Bae JS, Chang IH, Kim KD, Lee J, Shin HD, Lee JY, Kim WJ, Kim W, Myung SC. Sequence variants of Toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol 2012; 30:225 - 32; http://dx.doi.org/10.1007/s00345-011-0690-3; PMID: 21553150
   PubMed Web of Science ®Google Scholar
• Zhang K, Zhou B, Wang Y, Rao L, Zhang L. The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis. Eur J Cancer 2013; 49:946 - 54; http://dx.doi.org/10.1016/j.ejca.2012.09.022; PMID: 23084080
   PubMed Web of Science ®Google Scholar
• Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, Krämer B, Körner C, Odenthal M, Schulze F, et al. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 2012; 130:1470 - 5; http://dx.doi.org/10.1002/ijc.26143; PMID: 21500195
   PubMed Web of Science ®Google Scholar
• Wang X, Li J, Xie W, Zhang W, Chang Y. Toll-like receptor 2 gene polymorphisms and cancer susceptibility: a meta-analysis. Neoplasma 2013; 60:459 - 67; http://dx.doi.org/10.4149/neo_2013_060; PMID: 23581420
   PubMed Web of Science ®Google Scholar
• Theodoropoulos GE, Saridakis V, Karantanos T, Michalopoulos NV, Zagouri F, Kontogianni P, Lymperi M, Gazouli M, Zografos GC. Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast 2012; 21:534 - 8; http://dx.doi.org/10.1016/j.breast.2012.04.001; PMID: 22560646
   PubMed Web of Science ®Google Scholar
• Zou TH, Wang ZH, Fang JY. Positive association between Toll-like receptor 4 gene +896A/G polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Tumour Biol 2013; 34:2441 - 50; http://dx.doi.org/10.1007/s13277-013-0795-y; PMID: 23592020
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst 2012; 104:1796 - 807; http://dx.doi.org/10.1093/jnci/djs436; PMID: 23197495
   PubMed Web of Science ®Google Scholar
• Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol 2010; 31:391 - 7; http://dx.doi.org/10.1016/j.it.2010.07.004; PMID: 20832362
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51 - 72; http://dx.doi.org/10.1146/annurev-immunol-032712-100008; PMID: 23157435
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860 - 75; http://dx.doi.org/10.1038/nrc3380; PMID: 23151605
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, Menger L, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30:61 - 9; http://dx.doi.org/10.1007/s10555-011-9273-4; PMID: 21249425
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. OncoImmunology 2013; 2:e25595; http://dx.doi.org/10.4161/onci.25595; PMID: 24319634
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74 - 88; http://dx.doi.org/10.1016/j.immuni.2013.06.014; PMID: 23890065
   PubMed Web of Science ®Google Scholar
• Demaria S, Vanpouille-Box C, Formenti SC, Adams S. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. OncoImmunology 2013; 2:e25997; http://dx.doi.org/10.4161/onci.25997; PMID: 24404422
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220:47 - 59; http://dx.doi.org/10.1111/j.1600-065X.2007.00573.x; PMID: 17979839
   PubMed Web of Science ®Google Scholar
• Ahmed A, Redmond HP, Wang JH. Links between Toll-like receptor 4 and breast cancer. OncoImmunology 2013; 2:e22945; http://dx.doi.org/10.4161/onci.22945; PMID: 23526132
   PubMedGoogle Scholar
• Tittarelli A, González FE, Pereda C, Mora G, Muñoz L, Saffie C, García T, Díaz D, Falcón C, Hermoso M, et al. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother 2012; 61:2067 - 77; http://dx.doi.org/10.1007/s00262-012-1268-7; PMID: 22552381
   PubMed Web of Science ®Google Scholar
• Hoffman ES, Smith RE, Renaud RC Jr.. From the analyst’s couch: TLR-targeted therapeutics. Nat Rev Drug Discov 2005; 4:879 - 80; http://dx.doi.org/10.1038/nrd1880; PMID: 16299917
   PubMed Web of Science ®Google Scholar
• Heldwein KA, Liang MD, Andresen TK, Thomas KE, Marty AM, Cuesta N, Vogel SN, Fenton MJ. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol 2003; 74:277 - 86; http://dx.doi.org/10.1189/jlb.0103026; PMID: 12885945
   PubMed Web of Science ®Google Scholar
• Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, Akira S, Kawata T, Azuma I, Toyoshima K, Seya T. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan. Infect Immun 2003; 71:4238 - 49; http://dx.doi.org/10.1128/IAI.71.8.4238-4249.2003; PMID: 12874299
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301 - 14; http://dx.doi.org/10.1016/S0140-6736(09)61248-4; PMID: 19586656
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Paavonen J. Sound efficacy of prophylactic HPV vaccination: Basics and implications. OncoImmunology 2012; 1:995 - 6; http://dx.doi.org/10.4161/onci.20011; PMID: 23162784
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196 - 200; http://dx.doi.org/10.1038/ni758; PMID: 11812998
   PubMed Web of Science ®Google Scholar
• Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. OncoImmunology 2012; 1:1661 - 3; http://dx.doi.org/10.4161/onci.22033; PMID: 23264929
   PubMed Web of Science ®Google Scholar
• Schön MP, Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008; 27:190 - 9; http://dx.doi.org/10.1038/sj.onc.1210913; PMID: 18176600
   PubMed Web of Science ®Google Scholar
• Walter A, Schäfer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, Schönewolf N, Dummer R, Bloch W, Werner S, et al. Aldara activates TLR7-independent immune defence. Nat Commun 2013; 4:1560; http://dx.doi.org/10.1038/ncomms2566; PMID: 23463003
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13:343 - 51; http://dx.doi.org/10.1038/ni.2224; PMID: 22430787
   PubMed Web of Science ®Google Scholar
• Okamoto H, Shoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967; 11:323 - 6; http://dx.doi.org/10.1111/j.1348-0421.1967.tb00350.x; PMID: 4875331
   PubMedGoogle Scholar
• Aranda F, Vacchelli E, Obrist F, Eggermont A, Fridman WH, Galon J, et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. OncoImmunology 2014; 3:e27297
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, et al. Trial Watch: Oncolytic viruses for cancer therapy. OncoImmunology 2014; 3 Forthcoming
   Google Scholar
• Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. OncoImmunology 2013; 2:e25238; http://dx.doi.org/10.4161/onci.25238; PMID: 24083080
   PubMed Web of Science ®Google Scholar
• Murad YM, Clay TM, Lyerly HK, Morse MA. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther 2007; 7:1257 - 66; http://dx.doi.org/10.1517/14712598.7.8.1257; PMID: 17696823
   PubMed Web of Science ®Google Scholar
• Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111:2170 - 80; http://dx.doi.org/10.1182/blood-2007-07-100362; PMID: 17925489
   PubMed Web of Science ®Google Scholar
• Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, Mather CB, Benner RJ, Meech SJ. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biol Ther 2013; 14:557 - 63; http://dx.doi.org/10.4161/cbt.24598; PMID: 23792641
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. OncoImmunology 2013; 2:e22789; http://dx.doi.org/10.4161/onci.22789; PMID: 23482847
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. OncoImmunology 2014; 3:e27048; http://dx.doi.org/10.4161/onci.27048; PMID: 24605265
   PubMed Web of Science ®Google Scholar
• Akhtar S, Maghfoor I. Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1830-1, author reply 1830-1;; http://dx.doi.org/10.1056/NEJM200206063462317PMID: 12050349
   PubMedGoogle Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235 - 42; http://dx.doi.org/10.1056/NEJMoa011795; PMID: 11807147
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, et al. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol 2013; 88:589 - 93; http://dx.doi.org/10.1002/ajh.23460; PMID: 23619698
   PubMed Web of Science ®Google Scholar
• Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs 1998; 7:1475 - 82; http://dx.doi.org/10.1517/13543784.7.9.1475; PMID: 15992044
   PubMedGoogle Scholar
• Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2010; 667:111 - 23; http://dx.doi.org/10.1007/978-1-4419-1603-7_10; PMID: 20665204
   PubMed Web of Science ®Google Scholar
• Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; 26:1375 - 86; http://dx.doi.org/10.1016/j.vaccine.2007.12.038; PMID: 18272264
   PubMed Web of Science ®Google Scholar
• Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 2004; 27:124 - 35; http://dx.doi.org/10.1097/00002371-200403000-00006; PMID: 14770084
   PubMed Web of Science ®Google Scholar
• Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 2013; 31:2413 - 20; http://dx.doi.org/10.1200/JCO.2012.43.7111; PMID: 23715572
   PubMed Web of Science ®Google Scholar
• Brichard VG, Godechal Q. MAGE-A3-specific anticancer immunotherapy in the clinical practice. OncoImmunology 2013; 2:e25995; http://dx.doi.org/10.4161/onci.25995; PMID: 24244898
   PubMed Web of Science ®Google Scholar
• Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013; 31:2388 - 95; http://dx.doi.org/10.1200/JCO.2012.44.3762; PMID: 23715562
   PubMed Web of Science ®Google Scholar
• Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, Iadarola MJ, London WT, Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975; 132:434 - 9; http://dx.doi.org/10.1093/infdis/132.4.434; PMID: 810520
   PubMed Web of Science ®Google Scholar
• Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. OncoImmunology 2013; 2:e24677; http://dx.doi.org/10.4161/onci.24677; PMID: 23894722
   PubMedGoogle Scholar
• Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, Vandenberg SR, Macdonald TJ, Durden DL. Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors. J Pediatr Hematol Oncol 2013; Forthcoming http://dx.doi.org/10.1097/MPH.0000000000000047; PMID: 24309609
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. OncoImmunology 2012; 1:1111 - 34; http://dx.doi.org/10.4161/onci.21494; PMID: 23170259
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. OncoImmunology 2013; 2:e25771; http://dx.doi.org/10.4161/onci.25771; PMID: 24286020
   PubMed Web of Science ®Google Scholar
• Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S, Slade HB, Tyring SK, Warren T, Sacks SL, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis 2007; 195:1324 - 31; http://dx.doi.org/10.1086/513276; PMID: 17397003
   PubMed Web of Science ®Google Scholar
• Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 2008; 21:69 - 87; http://dx.doi.org/10.1358/dnp.2008.21.2.1188193; PMID: 18389099
   PubMed Web of Science ®Google Scholar
• Meyer T, Surber C, French LE, Stockfleth E. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs 2013; 22:149 - 59; http://dx.doi.org/10.1517/13543784.2013.749236; PMID: 23205468
   PubMed Web of Science ®Google Scholar
• Lai JP, Rosenberg AZ, Miettinen MM, Lee CC. NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target. OncoImmunology 2012; 1:1409 - 10; http://dx.doi.org/10.4161/onci.21059; PMID: 23243610
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. OncoImmunology 2014; 3:e27297; http://dx.doi.org/10.4161/onci.27297; PMID: 24701370
   PubMed Web of Science ®Google Scholar
• Paleja B, Anand A, Chaukar D, D’Cruz A, Chiplunkar S. Decreased functional response to Toll like receptor ligands in patients with oral cancer. Hum Immunol 2013; 74:927 - 36; http://dx.doi.org/10.1016/j.humimm.2013.04.018; PMID: 23628388
   PubMed Web of Science ®Google Scholar
• Newton MR, Askeland EJ, Andresen ED, Chehval VA, Wang X, Askeland RW, O’Donnell MA, Luo Y. Anti-interleukin-10R1 monoclonal antibody in combination with BCG is protective against bladder cancer metastasis in a murine orthotopic tumor model and demonstrates systemic specific antitumor immunity. Clin Exp Immunol 2014; Forthcoming http://dx.doi.org/10.1111/cei.12315; PMID: 24593764
   PubMed Web of Science ®Google Scholar
• Luo Y. Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity. OncoImmunology 2012; 1:1183 - 5; http://dx.doi.org/10.4161/onci.20640; PMID: 23170273
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 2009; 27:1787 - 96; http://dx.doi.org/10.1016/j.vaccine.2009.01.091; PMID: 19208455
   PubMed Web of Science ®Google Scholar
• White K, Rades T, Kearns P, Toth I, Hook S. Immunogenicity of liposomes containing lipid core peptides and the adjuvant Quil A. Pharm Res 2006; 23:1473 - 81; http://dx.doi.org/10.1007/s11095-006-0272-z; PMID: 16779706
   PubMed Web of Science ®Google Scholar
• Perret R, Sierro SR, Botelho NK, Corgnac S, Donda A, Romero P. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res 2013; 73:6597 - 608; http://dx.doi.org/10.1158/0008-5472.CAN-13-0875; PMID: 24048821
   PubMed Web of Science ®Google Scholar
• Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA, White D, Doherty E, Dranoff G, Mooney DJ. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res 2014; 74:1670 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-13-0777; PMID: 24480625
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2014; 21:69 - 78; http://dx.doi.org/10.1038/cdd.2013.72; PMID: 23811849
   PubMed Web of Science ®Google Scholar
• Tai LH, Zhang J, Scott KJ, de Souza CT, Alkayyal AA, Ananth AA, Sahi S, Adair RA, Mahmoud AB, Sad S, et al. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin Cancer Res 2013; 19:5104 - 15; http://dx.doi.org/10.1158/1078-0432.CCR-13-0246; PMID: 23881927
   PubMed Web of Science ®Google Scholar
• Huang SW, Kao JK, Wu CY, Wang ST, Lee HC, Liang SM, Chen YJ, Shieh JJ. Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells. Oncotarget 2014; 5:1352-62;PMID: 24658058
   PubMedGoogle Scholar
• Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12:829 - 46; http://dx.doi.org/10.1038/nrd4145; PMID: 24113830
   PubMed Web of Science ®Google Scholar
• Köchling J, Prada J, Bahrami M, Stripecke R, Seeger K, Henze G, Wittig B, Schmidt M. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 2008; 26:4669 - 75; http://dx.doi.org/10.1016/j.vaccine.2008.06.094; PMID: 18639600
   PubMed Web of Science ®Google Scholar
• Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, Coler RN, Reed SG. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses. Vaccine 2013; 31:5848 - 55; http://dx.doi.org/10.1016/j.vaccine.2013.09.069; PMID: 24120675
   PubMed Web of Science ®Google Scholar
• Schneider LP, Schoonderwoerd AJ, Moutaftsi M, Howard RF, Reed SG, de Jong EC, Teunissen MB. Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine 2012; 30:4216 - 24; http://dx.doi.org/10.1016/j.vaccine.2012.04.051; PMID: 22542815
   PubMed Web of Science ®Google Scholar
• Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, Hudson TE, Shaverdian N, O’Donnell J, Desbien AL, Reed SG, et al. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur J Immunol 2013; 43:2398 - 408; http://dx.doi.org/10.1002/eji.201243124; PMID: 23716300
   PubMed Web of Science ®Google Scholar
• Prior S, Fleck RA, Gillett ML, Rigsby PR, Corbel MJ, Stacey GN, Xing DK. Evaluation of adenyl cyclase toxin constructs from Bordetella pertussis as candidate vaccine components in an in vitro model of complement-dependent intraphagocytic killing. Vaccine 2006; 24:4794 - 803; http://dx.doi.org/10.1016/j.vaccine.2006.03.065; PMID: 16675078
   PubMed Web of Science ®Google Scholar
• Mackova J, Stasikova J, Kutinova L, Masin J, Hainz P, Simsova M, Gabriel P, Sebo P, Nemeckova S. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara. Cancer Immunol Immunother 2006; 55:39 - 46; http://dx.doi.org/10.1007/s00262-005-0700-7; PMID: 15926077
   PubMed Web of Science ®Google Scholar
• Fayolle C, Ladant D, Karimova G, Ullmann A, Leclerc C. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J Immunol 1999; 162:4157 - 62; PMID: 10201941
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330 - 6; http://dx.doi.org/10.1200/JCO.2010.30.7744; PMID: 21149657
   PubMed Web of Science ®Google Scholar
• Ziccheddu G, Proietti E, Moschella F. The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy. OncoImmunology 2013; 2:e25789; http://dx.doi.org/10.4161/onci.25789; PMID: 24244905
   PubMed Web of Science ®Google Scholar
• Waldron TJ, Quatromoni JG, Karakasheva TA, Singhal S, Rustgi AK. Myeloid derived suppressor cells: Targets for therapy. OncoImmunology 2013; 2:e24117; http://dx.doi.org/10.4161/onci.24117; PMID: 23734336
   PubMed Web of Science ®Google Scholar
• Su S, Zhou H, Xue M, Liu JY, Ding L, Cao M, Zhou ZX, Hu HM, Wang LX. Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models. Asian Pac J Cancer Prev 2013; 14:3109 - 16; http://dx.doi.org/10.7314/APJCP.2013.14.5.3109; PMID: 23803088
   PubMed Web of Science ®Google Scholar
• Li Y, Wang LX, Pang P, Cui Z, Aung S, Haley D, Fox BA, Urba WJ, Hu HM. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 2011; 17:7047 - 57; http://dx.doi.org/10.1158/1078-0432.CCR-11-0951; PMID: 22068657
   PubMed Web of Science ®Google Scholar
• Twitty CG, Jensen SM, Hu HM, Fox BA. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res 2011; 17:6467 - 81; http://dx.doi.org/10.1158/1078-0432.CCR-11-0812; PMID: 21810919
   PubMed Web of Science ®Google Scholar
• Aditya S, Gupta S. Ingenol mebutate: A novel topical drug for actinic keratosis. Indian Dermatol Online J 2013; 4:246-9;; http://dx.doi.org/10.4103/2229-5178.115538PMID: 23984250
   PubMedGoogle Scholar
• Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 2013; 149:666 - 70; http://dx.doi.org/10.1001/jamadermatol.2013.2766; PMID: 23553119
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366:1010 - 9; http://dx.doi.org/10.1056/NEJMoa1111170; PMID: 22417254
   PubMed Web of Science ®Google Scholar
• Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013; 258:879 - 86; http://dx.doi.org/10.1097/SLA.0b013e318292919e; PMID: 23657083
   PubMed Web of Science ®Google Scholar
• Vasir B, Zarwan C, Ahmad R, Crawford KD, Rajabi H, Matsuoka K, Rosenblatt J, Wu Z, Mills H, Kufe D, et al. Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). J Immunother 2012; 35:555 - 69; http://dx.doi.org/10.1097/CJI.0b013e31826a73de; PMID: 22892452
   PubMed Web of Science ®Google Scholar
• Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011; 17:7164 - 73; http://dx.doi.org/10.1158/1078-0432.CCR-11-0649; PMID: 22068656
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther 2007; 7:543 - 54; http://dx.doi.org/10.1517/14712598.7.4.543; PMID: 17373905
   PubMed Web of Science ®Google Scholar
• Petrulio CA, Kaufman HL. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines 2006; 5:9 - 19; http://dx.doi.org/10.1586/14760584.5.1.9; PMID: 16451103
   PubMed Web of Science ®Google Scholar
• Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012; 135:1042 - 54; http://dx.doi.org/10.1093/brain/aws042; PMID: 22418738
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J, NABTT CNS Consortium. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16:2443 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-09-3106; PMID: 20371685
   PubMed Web of Science ®Google Scholar
• Akilov OE, Grant C, Frye R, Bates S, Piekarz R, Geskin LJ. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions. Br J Dermatol 2012; 167:194 - 7; http://dx.doi.org/10.1111/j.1365-2133.2012.10905.x; PMID: 22372971
   PubMed Web of Science ®Google Scholar
• Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70:273 - 86; http://dx.doi.org/10.2165/11532190-000000000-00000; PMID: 20166766
   PubMed Web of Science ®Google Scholar
• West AC, Smyth MJ, Johnstone RW. The anticancer effects of HDAC inhibitors require the immune system. OncoImmunology 2014; 3:e27414; http://dx.doi.org/10.4161/onci.27414; PMID: 24701376
   PubMed Web of Science ®Google Scholar
• Adamopoulou E, Naumann U. HDAC inhibitors and their potential applications to glioblastoma therapy. OncoImmunology 2013; 2:e25219; http://dx.doi.org/10.4161/onci.25219; PMID: 24167760
   PubMed Web of Science ®Google Scholar
• Lim SN, Kuhn S, Hyde E, Ronchese F. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy. J Immunother 2012; 35:670 - 9; http://dx.doi.org/10.1097/CJI.0b013e318270e135; PMID: 23090076
   PubMed Web of Science ®Google Scholar
• Hennies CM, Reboulet RA, Garcia Z, Nierkens S, Wolkers MC, Janssen EM. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo. Clin Exp Immunol 2011; 163:381 - 91; http://dx.doi.org/10.1111/j.1365-2249.2010.04305.x; PMID: 21235535
   PubMed Web of Science ®Google Scholar
• Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 2009; 69:7747 - 55; http://dx.doi.org/10.1158/0008-5472.CAN-08-3289; PMID: 19738077
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Tel J, Benitez-Ribas D, Torensma R, Figdor CG. Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol 2011; 48:810 - 7; http://dx.doi.org/10.1016/j.molimm.2010.12.022; PMID: 21257206
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJ. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 2010; 116:564 - 74; http://dx.doi.org/10.1182/blood-2009-11-251884; PMID: 20424184
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Mavilio D, Lugli E. Inhibiting the inhibitors: Checkpoints blockade in solid tumors. OncoImmunology 2013; 2:e26535; http://dx.doi.org/10.4161/onci.26535; PMID: 24244910
   PubMedGoogle Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S. M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26;; http://dx.doi.org/10.1056/NEJMoa1104621PMID: 21639810
   PubMedGoogle Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122 - 33; http://dx.doi.org/10.1056/NEJMoa1302369; PMID: 23724867
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73:6900 - 12; http://dx.doi.org/10.1158/0008-5472.CAN-13-1550; PMID: 23975756
   PubMed Web of Science ®Google Scholar
• Williams EL, Dunn SN, James S, Johnson PW, Cragg MS, Glennie MJ, Gray JC. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res 2013; 19:3545 - 55; http://dx.doi.org/10.1158/1078-0432.CCR-12-3226; PMID: 23649004
   PubMed Web of Science ®Google Scholar
• Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33:225 - 35; http://dx.doi.org/10.1097/CJI.0b013e3181c01fcb; PMID: 20445343
   PubMed Web of Science ®Google Scholar